The estimated Net Worth of Hugh M Cole is at least $1.37 Million dollars as of 9 January 2023. Mr. Cole owns over 16,634 units of Jounce Therapeutics Inc stock worth over $206,954 and over the last 7 years he sold JNCE stock worth over $382,975. In addition, he makes $783,124 as Chief Business Officer and Head of Corporate Development at Jounce Therapeutics Inc.
Hugh has made over 8 trades of the Jounce Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 16,634 units of JNCE stock worth $18,464 on 9 January 2023.
The largest trade he's ever made was selling 18,000 units of Jounce Therapeutics Inc stock on 22 January 2021 worth over $215,100. On average, Hugh trades about 3,309 units every 93 days since 2018. As of 9 January 2023 he still owns at least 110,082 units of Jounce Therapeutics Inc stock.
You can see the complete history of Mr. Cole stock trades at the bottom of the page.
Hugh M. Cole serves as Chief Business Officer, Head of Corporate Development of the Company. Mr. Cole joined Jounce in August 2017 as our chief business officer and head of corporate development. Previously, Mr. Cole served as chief business officer for ARIAD Pharmaceuticals, Inc., an oncology company, from March 2014 to June 2017, where he led numerous business development transactions. Mr. Cole earned his M.B.A. in health care management and finance at the Wharton School of Business and his A.B. in chemistry from Harvard University.
As the Chief Business Officer and Head of Corporate Development of Jounce Therapeutics Inc, the total compensation of Hugh Cole at Jounce Therapeutics Inc is $783,124. There are 3 executives at Jounce Therapeutics Inc getting paid more, with Kimberlee Drapkin having the highest compensation of $2,032,250.
Hugh Cole is 55, he's been the Chief Business Officer and Head of Corporate Development of Jounce Therapeutics Inc since 2017. There are 10 older and 4 younger executives at Jounce Therapeutics Inc. The oldest executive at Jounce Therapeutics Inc is Dr. Louis M. Weiner M.D., 69, who is the Founder.
Hugh's mailing address filed with the SEC is 780 Memorial Dr, Cambridge, MA 02139, USA.
Over the last 8 years, insiders at Jounce Therapeutics Inc have traded over $39,574,093 worth of Jounce Therapeutics Inc stock and bought 724,587 units worth $10,288,083 . The most active insiders traders include Kevin Ctang Capital Managem..., Harbor Master Investors (Ca..., and Rock Ventures Ii, L.P.Third.... On average, Jounce Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $171,610. The most recent stock trade was executed by Richard /Ca/ Murray on 4 April 2023, trading 39,228 units of JNCE stock currently worth $72,572.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.
Jounce Therapeutics Inc executives and other stock owners filed with the SEC include: